Literature DB >> 20656791

Resistance to transforming growth factor β-mediated tumor suppression in melanoma: are multiple mechanisms in place?

Ahmed Lasfar1, Karine A Cohen-Solal.   

Abstract

Resistance to transforming growth factor (TGF) β-mediated tumor suppression in melanoma appears to be a crucial step in tumor aggressiveness since it is usually coupled with the ability of TGFβ to drive the oncogenic process via autocrine and paracrine effects. In this review, we will focus mainly on the mechanisms of escape from TGFβ-induced cell cycle arrest because the mechanisms of resistance to TGFβ-mediated apoptosis are still essentially speculative. As expected, some of these mechanisms can directly affect the function of the main downstream effectors of TGFβ, Smad2 and Smad3, resulting in compromised Smad-mediated antiproliferative activity. Other mechanisms can counteract or overcome TGFβ-mediated cell cycle arrest independently of the Smads. In melanoma, some models of resistance to TGFβ have been suggested and will be described. In addition, we propose additional models of resistance taking into consideration the information available on the dysregulation of fundamental cellular effectors and signaling pathways in melanoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20656791      PMCID: PMC2981460          DOI: 10.1093/carcin/bgq155

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  112 in total

Review 1.  How to make a melanoma: what do we know of the primary clonal events?

Authors:  Dorothy C Bennett
Journal:  Pigment Cell Melanoma Res       Date:  2008-02       Impact factor: 4.693

Review 2.  Transforming growth factor-beta in cutaneous melanoma.

Authors:  Delphine Javelaud; Vasileia-Ismini Alexaki; Alain Mauviel
Journal:  Pigment Cell Melanoma Res       Date:  2008-04       Impact factor: 4.693

3.  Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma.

Authors:  Koichi Matsuzaki; Miki Murata; Katsunori Yoshida; Go Sekimoto; Yoshiko Uemura; Noriko Sakaida; Masaki Kaibori; Yasuo Kamiyama; Mikio Nishizawa; Junichi Fujisawa; Kazuichi Okazaki; Toshihito Seki
Journal:  Hepatology       Date:  2007-07       Impact factor: 17.425

Review 4.  PI3K/PTEN signaling in tumorigenesis and angiogenesis.

Authors:  Bing-Hua Jiang; Ling-Zhi Liu
Journal:  Biochim Biophys Acta       Date:  2007-09-29

5.  Exposure of normal human melanocytes to a tumor promoting phorbol ester reverses growth suppression by transforming growth factor beta.

Authors:  Melanthia Stavroulaki; Dimitris Kardassis; Ekaterini Chatzaki; George Sakellaris; Carsten Lindschau; Hermann Haller; Androniki Tosca; Konstantin Krasagakis
Journal:  J Cell Physiol       Date:  2008-02       Impact factor: 6.384

Review 6.  FOXOs, cancer and regulation of apoptosis.

Authors:  Z Fu; D J Tindall
Journal:  Oncogene       Date:  2008-04-07       Impact factor: 9.867

7.  In vivo switching of human melanoma cells between proliferative and invasive states.

Authors:  Keith S Hoek; Ossia M Eichhoff; Natalie C Schlegel; Udo Döbbeling; Nikita Kobert; Leo Schaerer; Silvio Hemmi; Reinhard Dummer
Journal:  Cancer Res       Date:  2008-02-01       Impact factor: 12.701

Review 8.  Understanding signaling cascades in melanoma.

Authors:  Pablo Lopez-Bergami; Boris Fitchman; Ze'ev Ronai
Journal:  Photochem Photobiol       Date:  2007-12-15       Impact factor: 3.421

9.  Reversible Smad-dependent signaling between tumor suppression and oncogenesis.

Authors:  Go Sekimoto; Koichi Matsuzaki; Katsunori Yoshida; Shigeo Mori; Miki Murata; Toshihito Seki; Hirofumi Matsui; Jun-ichi Fujisawa; Kazuichi Okazaki
Journal:  Cancer Res       Date:  2007-06-01       Impact factor: 12.701

10.  Arkadia activates Smad3/Smad4-dependent transcription by triggering signal-induced SnoN degradation.

Authors:  Laurence Levy; Michael Howell; Debipriya Das; Sean Harkin; Vasso Episkopou; Caroline S Hill
Journal:  Mol Cell Biol       Date:  2007-06-25       Impact factor: 4.272

View more
  21 in total

Review 1.  Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression.

Authors:  Rita Nahta; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Rafaela Andrade-Vieira; Sarah N Bay; Dustin G Brown; Gloria M Calaf; Robert C Castellino; Karine A Cohen-Solal; Annamaria Colacci; Nichola Cruickshanks; Paul Dent; Riccardo Di Fiore; Stefano Forte; Gary S Goldberg; Roslida A Hamid; Harini Krishnan; Dale W Laird; Ahmed Lasfar; Paola A Marignani; Lorenzo Memeo; Chiara Mondello; Christian C Naus; Richard Ponce-Cusi; Jayadev Raju; Debasish Roy; Rabindra Roy; Elizabeth P Ryan; Hosni K Salem; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Renza Vento; Jan Vondráček; Mark Wade; Jordan Woodrick; William H Bisson
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

2.  Constitutive Smad linker phosphorylation in melanoma: a mechanism of resistance to transforming growth factor-β-mediated growth inhibition.

Authors:  Karine A Cohen-Solal; Kim T Merrigan; Joseph L-K Chan; James S Goydos; Wenjin Chen; David J Foran; Fang Liu; Ahmed Lasfar; Michael Reiss
Journal:  Pigment Cell Melanoma Res       Date:  2011-04-28       Impact factor: 4.693

3.  EWI-2 negatively regulates TGF-β signaling leading to altered melanoma growth and metastasis.

Authors:  Hong-Xing Wang; Chandan Sharma; Konstantin Knoblich; Scott R Granter; Martin E Hemler
Journal:  Cell Res       Date:  2015-02-06       Impact factor: 25.617

4.  RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion.

Authors:  Rajeev K Boregowda; Oyenike O Olabisi; Walid Abushahba; Byeong-Seon Jeong; Keneshia K Haenssen; Wenjin Chen; Marina Chekmareva; Ahmed Lasfar; David J Foran; James S Goydos; Karine A Cohen-Solal
Journal:  Cancer Lett       Date:  2014-03-18       Impact factor: 8.679

5.  Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment.

Authors:  Brent A Hanks; Alisha Holtzhausen; Katherine S Evans; Rebekah Jamieson; Petra Gimpel; Olivia M Campbell; Melissa Hector-Greene; Lihong Sun; Alok Tewari; Amanda George; Mark Starr; Andrew B Nixon; Christi Augustine; Georgia Beasley; Douglas S Tyler; Takayu Osada; Michael A Morse; Leona Ling; H Kim Lyerly; Gerard C Blobe
Journal:  J Clin Invest       Date:  2013-08-08       Impact factor: 14.808

6.  Snowball: resampling combined with distance-based regression to discover transcriptional consequences of a driver mutation.

Authors:  Yaomin Xu; Xingyi Guo; Jiayang Sun; Zhongming Zhao
Journal:  Bioinformatics       Date:  2014-09-05       Impact factor: 6.937

7.  CTGF is overexpressed in malignant melanoma and promotes cell invasion and migration.

Authors:  S Braig; S Wallner; B Junglas; R Fuchshofer; A-K Bosserhoff
Journal:  Br J Cancer       Date:  2011-06-14       Impact factor: 7.640

Review 8.  Interferon lambda: a new sword in cancer immunotherapy.

Authors:  Ahmed Lasfar; Walid Abushahba; Murugabaskar Balan; Karine A Cohen-Solal
Journal:  Clin Dev Immunol       Date:  2011-12-06

9.  Insights into the Transforming Growth Factor-β Signaling Pathway in Cutaneous Melanoma.

Authors:  Carole Yolande Perrot; Delphine Javelaud; Alain Mauviel
Journal:  Ann Dermatol       Date:  2013-05       Impact factor: 1.444

10.  Non-canonical Smads phosphorylation induced by the glutamate release inhibitor, riluzole, through GSK3 activation in melanoma.

Authors:  Walid Abushahba; Oyenike O Olabisi; Byeong-Seon Jeong; Rajeev K Boregowda; Yu Wen; Fang Liu; James S Goydos; Ahmed Lasfar; Karine A Cohen-Solal
Journal:  PLoS One       Date:  2012-10-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.